ATE141285T1 - Bispezifische monoklonale antikörper, ihre produktion und verwendung - Google Patents
Bispezifische monoklonale antikörper, ihre produktion und verwendungInfo
- Publication number
- ATE141285T1 ATE141285T1 AT91104844T AT91104844T ATE141285T1 AT E141285 T1 ATE141285 T1 AT E141285T1 AT 91104844 T AT91104844 T AT 91104844T AT 91104844 T AT91104844 T AT 91104844T AT E141285 T1 ATE141285 T1 AT E141285T1
- Authority
- AT
- Austria
- Prior art keywords
- production
- monoclonal antibodies
- bispecific monoclonal
- bispecific
- substance
- Prior art date
Links
- 230000002537 thrombolytic effect Effects 0.000 abstract 3
- 239000000126 substance Substances 0.000 abstract 2
- 239000003527 fibrinolytic agent Substances 0.000 abstract 1
- 229960000103 thrombolytic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8898590 | 1990-04-02 | ||
| JP17712190 | 1990-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE141285T1 true ATE141285T1 (de) | 1996-08-15 |
Family
ID=26430304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT91104844T ATE141285T1 (de) | 1990-04-02 | 1991-03-27 | Bispezifische monoklonale antikörper, ihre produktion und verwendung |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5496549A (en, 2012) |
| EP (1) | EP0450479B1 (en, 2012) |
| KR (1) | KR910018039A (en, 2012) |
| AT (1) | ATE141285T1 (en, 2012) |
| CA (1) | CA2039259A1 (en, 2012) |
| DE (1) | DE69121272T2 (en, 2012) |
| HU (1) | HUT63203A (en, 2012) |
| IE (1) | IE76288B1 (en, 2012) |
| TW (1) | TW212184B (en, 2012) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001355A (en) * | 1982-12-14 | 1999-12-14 | Dowdle; Eugene Bernard Davey | Pro-tPA for the treatment of thrombosis, embolism and related conditions |
| US6017512A (en) * | 1992-06-23 | 2000-01-25 | Diatide, Inc. | Radiolabeled peptides |
| US5620675A (en) * | 1992-06-23 | 1997-04-15 | Diatech, Inc. | Radioactive peptides |
| CN1162184C (zh) * | 1994-07-11 | 2004-08-18 | 德克萨斯州立大学董事会 | 用于脉管系统特异性凝血的组合物及其应用 |
| US5869274A (en) * | 1995-08-09 | 1999-02-09 | Zymed Laboratories, Inc. | Immuno-histochemical method that reduces background staining |
| US6524553B2 (en) | 1998-03-31 | 2003-02-25 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
| US6548663B1 (en) | 1998-03-31 | 2003-04-15 | Bristol-Myers Squibb Pharma Company | Benzodiazepine vitronectin receptor antagonist pharmaceuticals |
| US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
| US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
| CA2349333A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
| US6511649B1 (en) | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
| US6794518B1 (en) | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| IL142958A0 (en) | 1998-12-18 | 2002-04-21 | Du Pont Pharm Co | Vitronectin receptor antagonist pharmaceuticals |
| US7660415B2 (en) * | 2000-08-03 | 2010-02-09 | Selinfreund Richard H | Method and apparatus for controlling access to storage media |
| UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| EP1562968B1 (en) | 2001-11-14 | 2013-08-21 | Janssen Biotech, Inc. | Anti-il-6 antibodies, compositions, methods and uses |
| US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
| AU2003271174A1 (en) * | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| JPWO2005035754A1 (ja) * | 2003-10-14 | 2006-12-21 | 中外製薬株式会社 | 機能蛋白質を代替する二種特異性抗体 |
| MXPA06000176A (es) | 2003-12-10 | 2006-06-27 | Millennium Pharm Inc | Anticuerpos anti-ccr2 humanizados y sus metodos de uso. |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| CA2603264C (en) * | 2005-04-08 | 2017-03-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor viii |
| JO3058B1 (ar) | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها |
| WO2006138429A2 (en) | 2005-06-16 | 2006-12-28 | The Feinstein Institute For Medical Research | Antibodies against hmgb1 and fragments thereof |
| LT2452694T (lt) | 2005-06-30 | 2019-02-25 | Janssen Biotech, Inc. | Anti-il-23 antikūnai, kompozicijos, būdai ir panaudojimai |
| PT3219328T (pt) | 2005-12-29 | 2020-08-28 | Janssen Biotech Inc | Anticorpos anti-il-23 humana, composições, método e usos |
| WO2007114319A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 抗体の血中動態を制御する方法 |
| EP4218801A3 (en) | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| EP2202245B1 (en) | 2007-09-26 | 2016-08-24 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
| TW201129384A (en) | 2010-02-10 | 2011-09-01 | Immunogen Inc | CD20 antibodies and uses thereof |
| SMT201800075T1 (it) | 2010-03-30 | 2018-03-08 | Janssen Biotech Inc | Anticorpi contro il-25 umanizzati |
| NZ603581A (en) | 2010-06-19 | 2015-05-29 | Sloan Kettering Inst Cancer | Anti-gd2 antibodies |
| KR101962483B1 (ko) | 2010-11-17 | 2019-03-29 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
| JP6482525B2 (ja) | 2013-03-15 | 2019-03-13 | メモリアル スローン ケタリング キャンサー センター | 高親和性抗ｇｄ２抗体 |
| EP3022229A1 (en) | 2013-07-15 | 2016-05-25 | Novo Nordisk A/S | Antibodies that bind urokinase plasminogen activator |
| RU2758952C1 (ru) | 2013-09-27 | 2021-11-03 | Чугаи Сейяку Кабусики Кайся | Способ получения полипептидного гетеромультимера |
| DK3712174T3 (da) | 2013-12-24 | 2022-04-25 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| TWI701435B (zh) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | 測定ｆｖｉｉｉ的反應性之方法 |
| TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體 |
| WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| AU2016263198C1 (en) | 2015-05-15 | 2023-10-05 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| CA2990360C (en) | 2015-06-24 | 2024-02-13 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
| WO2017110980A1 (ja) | 2015-12-25 | 2017-06-29 | 中外製薬株式会社 | 増強された活性を有する抗体及びその改変方法 |
| WO2017115773A1 (ja) | 2015-12-28 | 2017-07-06 | 中外製薬株式会社 | Ｆｃ領域含有ポリペプチドの精製を効率化するための方法 |
| CN109069626A (zh) | 2016-02-12 | 2018-12-21 | 詹森药业有限公司 | 抗-vista(b7h5)抗体 |
| WO2017172771A2 (en) | 2016-03-29 | 2017-10-05 | Janssen Biotech, Inc. | Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody |
| WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
| CA3035081A1 (en) | 2016-09-02 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
| IL265144B2 (en) | 2016-09-06 | 2024-10-01 | Chugai Pharmaceutical Co Ltd | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
| KR20190059305A (ko) | 2016-09-30 | 2019-05-30 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법 |
| CA3044244A1 (en) | 2016-11-16 | 2018-05-24 | Janssen Biotech, Inc. | Method of treating psoriasis with anti-il23 specific antibody |
| TW201825515A (zh) | 2017-01-04 | 2018-07-16 | 美商伊繆諾金公司 | Ｍｅｔ抗體以及其免疫結合物及用途 |
| IL268007B2 (en) | 2017-01-30 | 2025-05-01 | Janssen Biotech Inc | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis |
| KR20240038148A (ko) | 2017-02-07 | 2024-03-22 | 얀센 바이오테크 인코포레이티드 | 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법 |
| CR20210381A (es) | 2017-09-29 | 2021-09-09 | Chugai Pharmaceutical Co Ltd | MOLÉCULA DE UNIÓN AL ANTÍGENO MULTIESPECÍFICA QUE TIENE ACTIVIDAD DE SUSTITUCIÓN DE LA FUNCIÓN DE COFACTOR DEL FACTOR VIII DE COAGULACIÓN DE SANGRE (FVIII) Y FORMULACIÓN FARMACÉUTICA QUE CONTIENE TAL MOLÉCULA COMO INGREDIENTE (Divisional Exp. 2020-0158) |
| MA54132A (fr) | 2018-03-05 | 2022-04-27 | Janssen Biotech Inc | Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23 |
| US20190345245A1 (en) | 2018-05-11 | 2019-11-14 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
| US11241417B2 (en) | 2018-06-21 | 2022-02-08 | Yumanity Therapeutics, Inc. | Compositions and methods for the treatment and prevention of neurological disorders |
| WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| EP3824295A4 (en) | 2018-07-18 | 2022-04-27 | Janssen Biotech, Inc. | PREDICTORS OF PROLONGED RESPONSE AFTER TREATMENT WITH AN ANTI-IL23 SPECIFIC ANTIBODY |
| BR112021009287A2 (pt) | 2018-11-20 | 2021-10-26 | Janssen Biotech, Inc. | Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23 |
| CA3135632A1 (en) | 2019-04-17 | 2020-10-22 | Novo Nordisk A/S | Bispecific antibodies |
| EP3972690A4 (en) | 2019-05-23 | 2023-07-05 | Janssen Biotech, Inc. | METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA |
| EP3976183A1 (en) | 2019-06-03 | 2022-04-06 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
| WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
| CN115515634A (zh) | 2020-05-05 | 2022-12-23 | 詹森生物科技公司 | 用抗il23特异性抗体治疗克罗恩病的方法 |
| CN115768466A (zh) | 2020-05-21 | 2023-03-07 | 詹森生物科技公司 | 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法 |
| US20220298236A1 (en) | 2021-03-12 | 2022-09-22 | Janssen Biotech, Inc. | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody |
| KR20230156764A (ko) | 2021-03-12 | 2023-11-14 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체에 의해 tnf 요법에 부적절한 반응을 보이는 건선성 관절염 환자를 치료하는 방법 |
| KR20240099352A (ko) | 2021-10-29 | 2024-06-28 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체로 크론병을 치료하는 방법 |
| JP2024544555A (ja) | 2021-11-15 | 2024-12-03 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｉｌ２３特異的抗体によるクローン病を処置する方法 |
| KR20240103043A (ko) | 2021-11-23 | 2024-07-03 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법 |
| JP2025512860A (ja) | 2022-03-30 | 2025-04-22 | ヤンセン バイオテツク，インコーポレーテツド | Ｉｌ－２３に特異的な抗体によって軽度から中等度の乾癬を治療する方法 |
| WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
| AU2023273357A1 (en) | 2022-05-18 | 2025-01-09 | Janssen Biotech, Inc. | Method for evaluating and treating psoriatic arthritis with il23 antibody |
| WO2024097639A1 (en) | 2022-10-31 | 2024-05-10 | Modernatx, Inc. | Hsa-binding antibodies and binding proteins and uses thereof |
| AU2023383916A1 (en) | 2022-11-22 | 2025-07-10 | Janssen Biotech, Inc. | Method of treating ulcerative colitis with anti-il23 specific antibody |
| WO2024118866A1 (en) | 2022-12-01 | 2024-06-06 | Modernatx, Inc. | Gpc3-specific antibodies, binding domains, and related proteins and uses thereof |
| WO2024206126A1 (en) | 2023-03-27 | 2024-10-03 | Modernatx, Inc. | Cd16-binding antibodies and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4714681A (en) * | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| JP3177776B2 (ja) * | 1988-09-27 | 2001-06-18 | 武田薬品工業株式会社 | ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤 |
| CA1213229A (en) * | 1982-04-12 | 1986-10-28 | Gary S. David | Antibodies having dual specificities, their preparation and uses therefor |
| AU595159B2 (en) * | 1984-04-23 | 1990-03-29 | Boston Biomedical Research Institute Incorporated | Bispecific antibody determinants |
| DE3426903A1 (de) * | 1984-07-20 | 1986-01-23 | Biotest Pharma GmbH, 6000 Frankfurt | Eine immunglobulinpraeparation in kombination mit einer anderen pharmakologisch wirksamen praeparation zur verwendung bei der behandlung von krankheiten |
| EP0241907A3 (en) * | 1986-04-14 | 1989-09-13 | The General Hospital Corporation | Heterobifunctional antibodies and method of use |
| US4889922A (en) * | 1986-08-13 | 1989-12-26 | Monsanto Co. | Monoclonal antibody specific for human colon fibroblast-derived T-PA |
| DE3909708A1 (de) * | 1989-03-23 | 1990-09-27 | Boehringer Mannheim Gmbh | Verfahren zur herstellung bispezifischer antikoerper |
-
1991
- 1991-03-20 TW TW080102180A patent/TW212184B/zh active
- 1991-03-27 DE DE69121272T patent/DE69121272T2/de not_active Expired - Fee Related
- 1991-03-27 AT AT91104844T patent/ATE141285T1/de not_active IP Right Cessation
- 1991-03-27 EP EP91104844A patent/EP0450479B1/en not_active Expired - Lifetime
- 1991-03-27 CA CA002039259A patent/CA2039259A1/en not_active Abandoned
- 1991-03-28 IE IE107991A patent/IE76288B1/en not_active IP Right Cessation
- 1991-03-28 HU HU911027A patent/HUT63203A/hu unknown
- 1991-04-02 KR KR1019910005314A patent/KR910018039A/ko not_active Ceased
-
1994
- 1994-12-06 US US08/350,497 patent/US5496549A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69121272D1 (de) | 1996-09-19 |
| DE69121272T2 (de) | 1997-01-09 |
| EP0450479A1 (en) | 1991-10-09 |
| KR910018039A (ko) | 1991-11-30 |
| IE911079A1 (en) | 1991-10-09 |
| HU911027D0 (en) | 1991-10-28 |
| TW212184B (en, 2012) | 1993-09-01 |
| EP0450479B1 (en) | 1996-08-14 |
| CA2039259A1 (en) | 1991-10-03 |
| US5496549A (en) | 1996-03-05 |
| HUT63203A (en) | 1993-07-28 |
| IE76288B1 (en) | 1997-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE141285T1 (de) | Bispezifische monoklonale antikörper, ihre produktion und verwendung | |
| FI101937B1 (fi) | Menetelmä monoklonaalisen vasta-aineen tuottamiseksi, joka reagoi ihmisen cachectiinin kanssa | |
| ES2106195T3 (es) | Anticuerpo igg aglicosilado anti cd3. | |
| GR1002306B (el) | Αναλυση και διαταξη συγκολλησεως στηλης. | |
| EP0101039A3 (en) | Monoclonal antibody, method of producing the same and use thereof | |
| IT8320550A0 (it) | Procedimento di purificazione peraffinita' in cui si impiegano anticorpi monoclonali. | |
| EP0141079A3 (en) | Monoclonal antibodies specific for membrane-associated antigens | |
| DE3887566D1 (de) | Pyridoxamin-Chelat Verbindungen, Mangan II chelate und ihre Verwendung als NMRI Kontrastmittel. | |
| NO870770L (no) | Fremgangsmte for fremstilling av monoklonale antistoffer. | |
| DE3885355D1 (de) | Monoklonale Antikörper. | |
| DE3177276D1 (de) | Monoklonale antikoerper. | |
| TR25161A (tr) | DÖNüS TITRESIMI ABSORBE EDICISI. | |
| EP0241907A3 (en) | Heterobifunctional antibodies and method of use | |
| NO159991C (no) | Vibrasjonstransportoer. | |
| FI852088A7 (fi) | Yhtenäiset, jäykät, vapaasti seisovat, kaasun läpäisevät, pienlämpötilasidoksiset hiekkaraemuotit. | |
| DE3883453D1 (de) | Hybride Plasminogenaktivatoren. | |
| DE3850993D1 (de) | Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2. | |
| FI883943A7 (fi) | Muunnetut plasminogeeni aktivaattorit. | |
| ATE140930T1 (de) | Hybride monoklonale antikörper, ihre herstellung und verwendung | |
| DE3874448D1 (de) | Schwingungsdaempfer. | |
| FR2726870B1 (fr) | Plateau durci pour un ensemble formant disque amortisseur, et son procede de fabrication | |
| DK176986A (da) | Monoklonalt anti-urokinase-antistof og produktion og anvendelse deraf | |
| FR2551002B1 (fr) | Engin mobile hybride rail-route | |
| EP0922761A4 (en) | MONOCLONAL ANTIBODY, SPECIFIC FOR ANTI-HUMAN FIBRINE MONOMER, METHOD FOR PRODUCING THE SAME, HYBRYDOM CELLS AND AN IMMUNOASSAY METHOD | |
| FI960566A7 (fi) | Monoklonaalinen vasta-aine, joka tunnistaa välisolun pinta-antigeenin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |